Skip to content

MaxCyte MXCT Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Ginkgo Bioworks logo
Ginkgo BioworksDNA
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
PDE
Pro-Dex, Inc.PDEX
Repligen logo
RepligenRGEN

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's operating lease right-of-use assets in other assets?
MaxCyte (MXCT) reported operating lease right-of-use assets in other assets of $10.7M in Q1 2026.
How has MaxCyte's operating lease right-of-use assets in other assets changed year-over-year?
MaxCyte's operating lease right-of-use assets in other assets decreased by 7.3% year-over-year, from $11.54M to $10.7M.
What is the long-term trend for MaxCyte's operating lease right-of-use assets in other assets?
Over 5 years (2020 to 2025), MaxCyte's operating lease right-of-use assets in other assets has grown at a 44.6% compound annual growth rate (CAGR), from $1.73M to $10.92M.